BOSTON, Dec 7 (Reuters) - Celgene Corp said on Monday that a trial of its cancer drug Revlimid showed it reduced the risk of disease progression in newly diagnosed patients with multiple myeloma by 50 ...

BOSTON, Dec 1 (Reuters) - Sales of Celgene Corp's cancer drug Revlimid could rise by more than a third if data due to be presented next Monday at the annual meeting of the American Society of ...

Celgene announced good news today about its blockbuster drug Revlimid. Did the stock jump as a result? Nope. Shares actually fell by more than 4%. Here's what happened. The U.S. Food and Drug ...

What a roll Celgene Corporation (NASDAQ:CELG) has been on lately. The company has experienced success after success in recent months. Celgene’s strength stems from its solid current product lineup, as ...

The post Why Do Americans Pay More for Prescription Drugs? appeared first on ProPublica.

Celgene ($CELG) has agreed to help fund a study of its blockbuster blood-cancer drug Revlimid in HIV patients. Bionor Pharma, a Norweigian biotech focused on HIV ...

We are downgrading Celgene Corporation (CELG) to Neutral from Outperform following the risk of cancer associated with the use of Revlimid as a maintenance therapy in patients suffering from multiple ...

Celgene (CELG +2%) heads north, albeit on lower-than-normal volume, after expected generic competitor Dr. Reddy's Laboratories (RDY +4.1%) failed to file for inter partes review of patents covering ...

Biopharmaceutical firm Celgene Corp. (CELG) focuses on various cancers including multiple myeloma and myelodysplastic syndromes, chronic lymphocyte leukemia and non-Hodgkin’s lymphoma, and ovarian, ...